SALMOSS Biotech

Executive Summary

SALMOSS Biotech, founded in 2020 in Chile, is developing sustainable bone graft materials using a novel non-mammal xenograft platform. Their flagship product, SALMOSS HAPS, aims to address the growing demand for safe and effective bone regeneration in dental and orthopedic applications while promoting a circular economy. By leveraging environmentally friendly sourcing, the company differentiates itself from traditional mammalian-derived xenografts, potentially reducing disease transmission risks and production costs.

Upcoming Catalysts (preview)

• Q1 2027Initiation of first-in-human clinical trial for SALMOSS HAPS in dental application50% success
• H2 2026Series A funding round60% success
• Q4 2026Strategic partnership with a major dental implant manufacturer40% success